Efficacy Of Prophylaxis With Norfloxacin in Transrectal Prostate Biopsy

Year 2000, Volume: 1 Issue: 2, 5 - 7, 01.08.2000

Ömer Öge Hakan Gemalmaz İzzet Koçak Burçin Özeren Mete Eyigör Haluk Erol

Abstract

Objective: Transrectal needle biopsy is the standard method in the diagnosis of prostate cancer. Various antibi-otic regimens have been used to reduce the complication of infection associated with this procedure. However, there is no well-established antibiotic regimen for patients undergoing transrectal biopsy of the prostate. Methods: Thirty-four patients undergoing transrectal biopsies of the prostate received 400 mg of norfloxacin twice a day starting 24 h before biopsy and continued for 1 week. In 48 hours and 7th day after transrectal needle biopsy were provided urine culture. Significant bacteriuria was defined as more than 1x105 colony / mL and febrile attack was accepted as high fever reaching 38.5°C. Results: Each rates of bacteraemia and urinary tract infection were 3%, and no patient developed sepsis. Discussion: The development of infection after transrectal biopsy of prostate is not rare. With the purpose of preventing such complications, intravenous antibiotics in high cost are commonly used. Norfloxacin prophylaxis for 1 week effectively minimizes such complications and it also has a low cost.

Keywords

norfloxacin, prostate, biopsy

References

• 1. Clements R. The changing role of transrektal ultrasound in the diagnosis of prostate cancer. Clin Radiol 1996; 51: 671-6.
• 2. Bissada NK, Rountree GA, Sulieman JS. Factors af￾fecting accuracy and morbidity in transrectal biopsy of the prostate. Surg Gyn Obs 1977; 145: 869-72.
• 3. Crawford ED, Haynes AL, Story MW, Borden TA. Prevention of urinary tract infection and sepsis follow￾ing transrectal prostatic biopsy. Br J Urol 1982; 127: 449-51.
• 4. Davison P, Malament M. Urinary contamination as a result of transrectal biopsy of the prostate. J Urol 1971; 105: 545-6.
• 5. Ruebush TK, McConville JH, Calia FM. A double￾blind study of trimetoprim-sulfamethoxazole prophy￾laxis in patients having transrectal biopsy of the pros￾tate. J Urol 1979; 122: 492-4.
• 6. Dowlen LW, Black NL, Politano VA. Complications of transrectal biopsy examination of the prostate. S M J 1974; 67:.1453-7.
• 7. Thompson PM, Talbot RW, Packham DA and Dulake C. Transrectal biopsy of the prostate and bacteraemia. Br J Surg 1980; 67: 127-31.
• 8. Taylor H M, Bingham JB. Antibiotic prophylaxis for transrectal prostate biopsy. J Antimic Chem 1997; 39: 115-7.
• 9. Fawcett DP, Eykyn S, Bultitude MI. Urinary tract in￾fection following trans-rectal biopsy of the prostate. Br J Urol 1975; 47: 679-81.
• 10. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and the review of the literature. J Urol 1998; 160: 2115-20.
• 11. Cooner WH, Mosley BR, Rutherford CL, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonog￾raphy, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-9.
• 12. Aus G, Hermansson CG, Hugosson J and Pedersen KV. Transrectal ultrasound examination of the prostate: com￾plications and acceptance by patients. Br J Urol 1993; 71: 460-3.
• 13. Sieber PR, Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Harpster LE. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997; 157: 2199-202.
• 14. Aus G, Ahlgren G, Bergdahl S, et al. Infection after transrectal core biopsies of the prostate: risk factors and antibiotic prophylaxis. Br J Urol 1996; 77: 851-5.